Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses

Bray et al., Antiviral Res., doi:10.1016/j.antiviral.2020.104805

Apr 2020

Source PDF All Studies Meta AnalysisMeta

Responses to Caly et al., and the author's reply. The original authors note that "ivermectin's key direct target in mammalian cells is a not a viral component, but a host protein important in intracellular transport; the fact that it is a host-directed agent (HDA) is almost certainly the basis of its broad-spectrum activity against a number of different RNA viruses in vitro. The way a HDA can reduce viral load is by inhibiting a key cellular process that the virus hijacks to enhance infection by suppressing the host antiviral response. Reducing viral load by even a modest amount by using a HDA at low dose early in infection can be the key to enabling the body's immune system to begin to mount the full antiviral response before the infection takes control."

Important missing comments or errors? Let us know.

Bray et al., 21 Apr 2020, preprint, 5 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Antiviral Research, Craig R Rayner, Karen Yeo, David Wesche, Lisa Almond, Michael Dodds, Patrick F Smith, Mark Sullivan

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

References

Baraka, Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus, Eur. J. Clin. Pharmacol

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res, doi:10.1016/j.antiviral.2020.104787

Caly, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res, doi:10.1016/j.antiviral.2020.104787

Crump, Omura, Ivermectin, 'wonder drug' from Japan: the human use perspective, Proc. Jpn. Acad. Ser. B Phys. Biol. Sci

Guzzo, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J. Clin. Pharmacol

Jans, Kylie, Caly, Druce, Catton et al., The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res

Merck, None, Mectizan NDA

Merck, Stromectol USPI

Navarro, Camprubí, Requena-Méndez, Buonfrate, Giorli et al., Safety of high-dose ivermectin: a systematic review and meta-analysis, J. Antimicrob. Chemother

Noël, Lima, Pharmacological aspects and clues for the rationale use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic, Lat. Am. J. Clin. Sci. Med. Technol

Pimenta, Silva, Noël, Ivermectin is a nonselective inhibitor of mammalian P-type ATPases, Naunyn-Schmied Arch. Pharmacol

Smit, Ochomo, Waterhouse, Kwambai, Abong'o et al., Pharmacokinetics-pharmacodynamics of high dose ivermectin with Dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL), Clin. Pharmacol. Ther

Smit, Pharmacokinetics-pharmacodynamics of high-dose ivermectin with dihydroartemisinin-piperaquine on mosquitocidal activity and QT-prolongation (IVERMAL), Clin. Pharmacol. Ther

Tay, Fraser, Chan, Moreland, Rathore et al., Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res, doi:10.1016/j.2013Sep

Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer

Yao, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0